Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment

Multiple Sclerosis Journal

Volumn 18, Issue 1, 2012, Pages 98-107

  Rigotti, D J ^a   Gass, A ^b   Achtnichts, L ^b   Inglese, M ^a   Babb, J S ^a   Naegelin, Y ^b   Hirsch, J ^b   Amann, M ^b   Kappos, L ^b   Gonen, O ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

multiple sclerosis (MS); Multiple Sclerosis Severity Scale (MSSS); N acetylaspartate (NAA); proton MR spectroscopy (1H MRS); whole brain NAA (WBNAA)

Indexed keywords

N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BRAIN LEVEL; BRAIN SIZE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PROTON NUCLEAR MAGNETIC RESONANCE; RATING SCALE;

EID: 84855936106     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511415142     Document Type: Article

References (54)

1. Hauser SL Harrison's principles of internal medicine. Isselbacher KJ Wilson JD Martin JB Fauci AS Kasper DL, ed. New York: McGraw-Hill ; 1994: 2287-2295.
2. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol. 1994 ; 36: S6 - S11
3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 ; 46: 907-911
4. Compston A, Coles A. Multiple sclerosis. Lancet. 2002 ; 359: 1221-1231 (Pubitemid 34304266)
5. Schwid SR, Bever CT. The cost of delaying treatment in multiple sclerosis. What is lost is not regained. Neurology. 2001 ; 56: 1620 (Pubitemid 32574557)
6. Clegg A, Bryant J. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opin Pharmacother. 2001 ; 2: 623-639 (Pubitemid 32427757)
7. Confavreux C, Vukusic S. The clinical epidemiology of multiple sclerosis. Neuroimaging Clin N Am. 2008 ; 18: 589-622
8. Rovaris M, Barkhof F, Calabrese M, et al. MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. Neurology. 2009 ; 72: 1693-1701
9. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000 ; 343: 1430-1438
10. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003 ; 126: 770-782 (Pubitemid 36372978)
11. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993 ; 116: 117-134 (Pubitemid 23087038)
12. Hirst C, Ingram G, Swingler R, Compston DA, Pickersgill T, Robertson NP. Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. J Neurol Neurosurg Psychiatry. 2008 ; 79: 1137-1143
13. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008 ; 131: 808-817 (Pubitemid 351294716)
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452 (Pubitemid 14237132)
15. Cohen J, Rudick R Multiple sclerosis therapeutics. 2007 ) Multiple sclerosis therapeutics3rd ed, Informa HealthCare. Informa HealthCare ; 2007:
16. Pachner AR, Steiner I. The multiple sclerosis severity score (MSSS) predicts disease severity over time. J Neurol Sci. 2009 ; 278: 66-70
17. Lassmann H. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models?. Exp Neurol. 2010 ; 225: 2-8
18. Arnold DL, De Stefano N, Narayanan S, Matthews PM Magnetic resonance spectroscopy in multiple sclerosis. Comi G, ed. Milan: Springer-Verlag Italia ; 2001: 61-67.
19. Benarroch EE. N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. Neurology. 2008 ; 70: 1353-1357 (Pubitemid 351550340)
20. Mainero C, De Stefano N, Iannucci G, et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology. 2001 ; 56: 1331-1334 (Pubitemid 32455293)
21. Mathiesen HK, Jonsson A, Tscherning T, et al. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol. 2006 ; 63: 533-536
22. Enzinger C, Ropele S, Strasser-Fuchs S, et al. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol. 2003 ; 60: 65-70 (Pubitemid 36078110)
23. Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. JNeurol. 2003 ; 250: 1407-1419 (Pubitemid 38121836)
24. Gonen O, Catalaa I, Babb JS, et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology. 2000 ; 54: 15-19 (Pubitemid 30038731)
25. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003 ; 126: 433-437 (Pubitemid 36172747)
26. Inglese M, Ge Y, Filippi M, Falini A, Grossman RI, Gonen O. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage. 2004 ; 21: 1825-1829 (Pubitemid 38446603)
27. Gonen O, Moriarty DM, Li BS, et al. Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations. Radiology. 2002 ; 225: 261-268
28. Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of 'benign' multiple sclerosis at 20 years. Neurology. 2007 ; 68: 496-500
29. Ramsaransing GS, De Keyser J. Benign course in multiple sclerosis: a review. Acta Neurol Scand. 2006 ; 113: 359-369 (Pubitemid 44046321)
30. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol. 2004 ; 56: 303-306 (Pubitemid 39037929)
31. Hu J, Javaid T, Arias-Mendoza F, Liu Z, McNamara R, Brown TR. A fast, reliable, automatic shimming procedure using 1 H chemical-shift-imaging spectroscopy. J Magn Reson B. 1995 ; 108: 213-219
32. De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001 ; 22: 529-539 (Pubitemid 32607736)
33. Ashburner J, Hutton C, Frackowiak R, Johnsrude I, Price C, Friston K. Identifying global anatomical differences: deformation-based morphometry. Hum Brain Mapp. 1998 ; 6: 348-357 (Pubitemid 28460591)
34. Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. 2001 ; 25: 466-475 (Pubitemid 32440803)
35. Smith SM, Rao A, De Stefano N, et al. Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage. 2007 ; 36: 1200-1206 (Pubitemid 47001738)
36. Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol. 2000 ; 12: 191-200 (Pubitemid 32843166)
37. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002 ; 17: 143-155 (Pubitemid 35253488)
38. Gonen O, Viswanathan AK, Catalaa I, Babb J, Udupa J, Grossman RI. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med. 1998 ; 40: 684-689 (Pubitemid 28493644)
39. Caramanos Z, Narayanan S, Arnold DL. 1 H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain. 2005 ; 128: 2483-2506 (Pubitemid 41552936)
40. Baslow MH. N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res. 2003 ; 28: 941-953 (Pubitemid 36438413)
41. Benedetti B, Rigotti DJ, Liu S, Filippi M, Grossman RI, Gonen O. Reproducibility of the whole-brain N-acetylaspartate level across institutions, MR scanners, and field strengths. AJNR Am J Neuroradiol. 2007 ; 28: 72-75 (Pubitemid 46147537)
42. Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol. 2003 ; 60: 989-994 (Pubitemid 36858359)
43. Matthews PM, De Stefano N, Narayanan S, et al. Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis. Semin Neurol. 1998 ; 18: 327-336 (Pubitemid 28488949)
44. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000 ; 48: 893-901
45. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007 ; 68: S22 - S31
46. Strasser-Fuchs S, Enzinger C, Ropele S, Wallner M, Fazekas F. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?. Mult Scler. 2008 ; 14: 205-211 (Pubitemid 351639629)
47. Traboulsee A, Dehmeshki J, Peters KR, et al. Disability in multiple sclerosis is related to normal-appearing brain tissue MTR histogram abnormalities. Mult Scler. 2003 ; 9: 566-573 (Pubitemid 37479404)
48. Ceccarelli A, Rocca MA, Pagani E, et al. The topographical distribution of tissue injury in benign MS: a 3 T multiparametric MRI study. Neuroimage. 2008 ; 39: 1499-1509
49. Rovaris M, Riccitelli G, Judica E, et al. Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology. 2008 ; 71: 1521-1526
50. Costelloe L, Thompson A, Walsh C, Tubridy N, Hutchinson M. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry. 2008 ; 79: 1245-1248
51. Rigotti DJ, Gonen O, Grossman RI, et al. Global N-acetylaspartate declines even in benign multiple sclerosis. AJNR Am J Neuroradiol. 2011 ; 32: 204-209
52. Güntner M, Herbert J, Neuhaus A, Daumer M. Steps towards a validation of a new severity-based MS classification system using the Ian McDonald MS Database. Mult Scler. 2008 ; 14: 100-110
53. Gonen O, Grossman RI. The accuracy of whole brain N-acetylaspartate quantification. Magn Reson Imaging. 2000 ; 18: 1255-1258 (Pubitemid 32121441)
54. Maudsley AA, Domenig C, Sheriff S. Reproducibility of serial whole-brain MR spectroscopic imaging. NMR Biomed. 2010 ; 23: 251-256